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Belgrade, Serbia; Bristol, United Kingdom; Enschede, Rotterdam, the Netherlands; and Ferrara, ItalyObjectives This study sought to study the efﬁcacy and safety of newer-generation drug-eluting stents
(DES) compared with bare-metal stents (BMS) in an appropriately powered population of patients with
ST-segment elevation myocardial infarction (STEMI).
Background Among patients with STEMI, early generation DES improved efﬁcacy but not safety
compared with BMS. Newer-generation DES, everolimus-eluting stents, and biolimus A9-eluting stents,
have been shown to improve clinical outcomes compared with early generation DES.
Methods Individual patient data for 2,665 STEMI patients enrolled in 2 large-scale randomized
clinical trials comparing newer-generation DES with BMS were pooled: 1,326 patients received
a newer-generation DES (everolimus-eluting stent or biolimus A9-eluting stent), whereas the
remaining 1,329 patients received a BMS. Random-effects models were used to assess differences
between the 2 groups for the device-oriented composite endpoint of cardiac death, target-vessel
reinfarction, and target-lesion revascularization and the patient-oriented composite endpoint of
all-cause death, any infarction, and any revascularization at 1 year.
Results Newer-generation DES substantially reduce the risk of the device-oriented composite
endpoint compared with BMS at 1 year (relative risk [RR]: 0.58; 95% conﬁdence interval [CI]: 0.43
to 0.79; p ¼ 0.0004). Similarly, the risk of the patient-oriented composite endpoint was lower with
newer-generation DES than BMS (RR: 0.78; 95% CI: 0.63 to 0.96; p¼ 0.02). Differences in favor of newer-
generation DES were driven by both a lower risk of repeat revascularization of the target lesion (RR:
0.33; 95% CI: 0.20 to 0.52; p < 0.0001) and a lower risk of target-vessel infarction (RR: 0.36; 95% CI: 0.14
to 0.92; p ¼ 0.03). Newer-generation DES also reduced the risk of deﬁnite stent thrombosis (RR: 0.35;
95% CI: 0.16 to 0.75; p ¼ 0.006) compared with BMS.
Conclusions Among patients with STEMI, newer-generation DES improve safety and efﬁcacy
compared with BMS throughout 1 year. It remains to be determined whether the differences in favor
of newer-generation DES are sustained during long-term follow-up. (J Am Coll Cardiol Intv
2014;7:55–63) ª 2014 by the American College of Cardiology Foundation
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56Early generation drug-eluting stents (DES), namely, p ¼ 0.019), the COMFORTABLE-AMI trial demon-
sirolimus-eluting stents and paclitaxel-eluting stents, have
been compared with bare-metal stents (BMS) in the clinical
setting of ST-segment elevation myocardial infarction
(STEMI) in several randomized controlled trials and
consistently showed a reduction in major adverse cardiac
events mainly related to a lower risk of repeat revasculari-
zation procedures (1–6).
Notwithstanding, concerns regarding the safety of DES in
STEMI patients have been repeatedly raised: pathological
analysis of autopsy specimens have revealed more inﬂam-
mation, ﬁbrin deposition, and uncovered struts among lesions
treated with early generation DES in patients with acute
myocardial infarction compared with those with stable
lesions, suggesting a differential healing response depending
on the underlying plaque morphology (7). Intracoronary in
vivo imaging studies have further substantiated these ﬁnd-From the *University Hospital Clinic
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Abbreviations
and Acronyms
BES = biolimus A9–eluting
stent(s)
BMS = bare-metal stent(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
DOCE = device-oriented
composite endpoint
EES = everolimus-eluting
stent(s)
HR = hazard ratio
POCE = patient-oriented
composite endpoint
RR = relative risk
STEMI = ST-segment
elevation myocardialings, highlighting an impaired
healing process of DES im-
planted in thrombotic compared
with stable lesions (8).
Newer-generation devices with
drug release from durable or
biodegradable polymer surface
coating may provide the basis for
improved biocompatibility and
vascular healing (9). The EXAM-
INATION (clinical Evaluation
of the Xience-V stent in Acute
Myocardial INfArcTION) and
COMFORTABLE-AMI (Com-
parison of Biolimus Eluted From
an Erodible Stent Coating With
Bare Metal Stents in Acute
ST-Elevation Myocardial Infarc-
tion) trials have tested the efﬁcacyof everolimus eluted fromdurable polymer (everolimus-eluting
stent [EES]) and of biolimus A9 eluted from biodegradable
polymer (biolimusA8–eluting stent [BES]) stents versusBMS,
respectively, in an all-comer STEMI population (10–13).
Whereas the EXAMINATION trial showed a signiﬁcant
reduction in stent thrombosis with the EES (0.9% vs. 2.5%,
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epted July 17, 2013.strated a signiﬁcant reduction in major adverse cardiac
events with the BES (4.3% vs. 8.7%, p ¼ 0.004) compared
with BMS. Nevertheless, neither of these 2 trials had a
sample size sufﬁciently powered to achieve all the safety and
efﬁcacy endpoints.
We sought, therefore, to determine whether the beneﬁts
of newer DES translate into improved safety compared with
BMS among patients with STEMI in an appropriately
powered patient population.
Methods
Patient population. We performed a patient-level pooled
analysis of the 2 largest multicenter, randomized clinical
trials comparing newer-generation DES, with either dura-
ble or biodegradable polymer, with BMS (Multilink
Vision, Abbott, Santa Clara, California; the Gazelle stent,
Biosensors Europe SA, Morges, Switzerland) in STEMI:
the EXAMINATION and the COMFORTABLE-AMI
trials. Detailed descriptions relating to the design of the 2
trials were reported elsewhere (12,13).
Procedural medications. During the procedure, all patients
received unfractionated heparin or bivalirudin, whereas
the use of glycoprotein IIb/IIIa antagonists was left at the
discretion of the operators. In the EXAMINATION trial,
all patients received aspirin (loading dose of 250 to 500 mg
and maintenance dose of 100 mg/day) and clopidogrel
(loading dose of at least 300 mg and maintenance dose of 75
mg/day). Neither prasugrel nor ticagrelol was approved
during the recruitment period. In the COMFORTABLE-
AMI, in the centers where prasugrel was available, an initial
dose of 60 mg (including patients pre-loaded with clopi-
dogrel) was administered followed by a daily dose of 10 mg.
If prasugrel was not available or contraindicated, clopidogrel
was administered at a loading dose of 600 mg, followed by
a dose of 75 mg twice daily for 7 days, and a maintenance
dose of 75 mg once daily thereafter. Dual antiplatelet
therapy was prescribed in both trials for at least 1 year in all
patients.
Endpoints and deﬁnitions. Pre-speciﬁed endpoints of this
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Table 1. Baseline and Procedural Characteristics
Drug-Eluting Stents
(N ¼ 1,326)
Bare-Metal Stents
(N ¼ 1,329) p Value
Age, yrs 60.77  11.96 61.09  12.29 0.502
Male 1,097 (82.73) 1,065 (80.14) 0.090
Body mass index, kg/m2 27.25  4.09 27.32  3.95 0.656
Cardiovascular risk factors
Diabetes mellitus 221 (16.68) 211 (15.88) 0.599
Hypertension 626 (47.25) 643 (48.38) 0.560
Hypercholesterolemia 678 (51.29) 629 (47.47) 0.052
Current smoker 644 (48.86) 687 (51.93) 0.120
Family history of
coronary artery disease
327 (25.83) 298 (23.63) 0.213
Previous cardiac events
Myocardial infarction 64 (4.83) 79 (5.94) 0.229
PCI 48 (3.62) 59 (4.44) 0.324
CABG 13 (0.98) 11 (0.83) 0.688
Clinical presentation
Primary PCI (<12 h) 1,160 (87.48) 1,159 (87.41) 1.000
Killip class II, III, or IV 120 (9.06) 113 (8.52) 0.632
Left ventricular ejection
fraction
49.98  10.95 50.36  9.93 0.405
Site of infarct-related artery 0.947
Left main 3 (0.23) 3 (0.23) 1.000
LAD 549 (41.40) 535 (40.29) 0.580
Left circumﬂex 184 (13.88) 197 (14.83) 0.507
Right circumﬂex 586 (44.19) 588 (44.28) 0.969
Saphenous vein graft 4 (0.30) 5 (0.38) 1.000
Angiographic and procedural
characteristics
TIMI ﬂow 0 to 2 before PCI 1,089 (82.38) 1,099 (83.26) 0.571
Thrombus aspiration 845 (63.73) 855 (64.38) 0.746
No. of vessels treated at
procedure
0.664
1 1,266 (95.48) 1,277 (96.16) 0.385
2 57 (4.30) 48 (3.61) 0.372
3 3 (0.23) 3 (0.23) 1.000
Treatment of LAD 566 (42.68) 547 (41.19) 0.455
Lesions and stenting
No. of lesions treated 1.18  0.44 1.18  0.44 0.907
Total stent length, mm 28.21  14.72 27.54  14.66 0.241
Maximum stent
diameter, mm
3.24  0.46 3.24  0.87 0.799
No. of stents implanted 1.44  0.70 1.43  0.75 0.683
Direct stenting 686 (52.25) 663 (50.69) 0.435
Overlapping stents 347 (26.19) 327 (24.70) 0.397
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; LAD ¼ left anterior descending artery; PCI ¼ percu-
taneous coronary interventions; TIMI ¼ Thrombolysis In Myocardial Infarction.
Table 2. Medication Used at Procedure, Discharge, and Follow-up
Drug-Eluting
Stents
(N ¼ 1,326)
Bare-Metal
Stents
(N ¼ 1,329) p Value
During primary PCI
Aspirin* 1,265 (95.47) 1,271 (95.71) 0.778
Clopidogrel* 1,183 (89.28) 1,177 (88.56) 0.578
Prasugrel* 231 (17.42) 238 (17.90) 0.857
Any DAPT*y 679 (90.41) 675 (90.36) 1.000
Unfractionated heparin 1,109 (83.63) 1,113 (83.75) 0.958
Low molecular weight heparin 81 (6.11) 90 (6.77) 0.527
Bivalirudin 123 (9.28) 123 (9.26) 1.000
Glycoprotein IIb/IIIa antagonists 566 (42.68) 545 (41.01) 0.387
At discharge
Aspirin 1,309 (99.47) 1,313 (99.47) 1.000
Any DAPT 1,306 (99.32) 1,310 (99.32) 1.000
At 30 days
Aspirin 1,230 (98.80) 1,247 (99.13) 0.437
Any DAPT 1,223 (98.15) 1,237 (98.41) 0.647
At 1 yr
Aspirin 1,187 (97.53) 1,185 (97.45) 0.898
Any DAPT 1,138 (93.43) 1,073 (88.24) <0.001
Values are n (%). *Loading dose or already taking for aspirin, clopidogrel, and prasugrel. yDAPT
was aspirin with clopidogrel in the EXAMINATION trial and aspirin with clopidogrel or prasugrel
in the COMFORTABLE-AMI trial.
DAPT ¼ dual antiplatelet therapy; PCI ¼ percutaneous coronary intervention.
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57(DOCE) of cardiac death, target vessel reinfarction and
ischemia-driven target lesion revascularization, and the
patient-oriented endpoint (POCE) of all-cause death, any
myocardial infarction, and any revascularization.
Cardiac death was deﬁned as death because of immediate
cardiac causes or complications related to the procedure,as well as any death in which a cardiac cause could not
be excluded. Myocardial infarction was deﬁned according
to the World Health Organization extended deﬁnition
(14). Target lesion revascularization was deﬁned as any
clinically indicated repeat revascularization (percutaneous
or surgical) of the target lesions. Additional endpoints
analyzed were the single components of the above-
mentioned endpoints. Stent thrombosis was deﬁned
according to the Academic Research Consortium criteria
(15).
Both trials used identical endpoint deﬁnitions, and the
chairman of the clinical event committee was the same, en-
suring a similar event adjudication process. All the endpoints
were evaluated at 1-year follow-up.
Statistical analysis. Continuous data are presented as mean
 SD or median (interquartile range). Categorical data are
presented as count and percentage. Comparison between
groups was done by a Student t test or chi-square test, as
appropriate. Meta-analysis was performed on individual
patient data according to intention to treat. Random-effects
models were used to assess differences in clinical outcomes
between newer generation DES and BMS for the pre-
speciﬁed DOCE of cardiac death, target-vessel infarction,
and target-lesion revascularization and the POCE of all-
cause death, any infarction, and any revascularization at
1 year. A 2-sided p value <0.05 was considered as statisti-
cally signiﬁcant. Statistical analysis was performed using the
Figure 1. Clinical Endpoints at 1 Year
Forrest plot with hazard ratios of each endpoint for individual trials and the pooled population. BMS ¼ bare-metal stent(s); CI ¼ conﬁdence interval; DES ¼ drug-eluting
stent(s); DOCE ¼ device-oriented primary composite endpoint (cardiac death, target vessel reinfarction, target lesion revascularization); HR ¼ hazard ratio;
POCE ¼ patient-oriented composite endpoint (all-cause death, any myocardial infarction, any revascularization); TLR ¼ target lesion revascularization;
TV ¼ target vessel; TVR ¼ target vessel revascularization.
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58STATA software version 12.1 (StataCorp, College Station,
Texas).
Results
Patient population. A total of 2,665 patients were included
in the present analysis; the EXAMINATION trial randomly
(1:1) assigned 1,504 patients to treatment with EES or
BMS, and the COMFORTABLE-AMI trial randomly
(1:1) assigned 1,161 patients to treatment with BES or
BMS. All patients were stratiﬁed according to the type of
stent implanted at the index procedure: 1,326 patients
received a newer-generation DES with either durable or
degradable polymer, whereas the remaining 1,329 patients
received a BMS.
Table 1 summarizes the baseline clinical characteristics of
the 2 groups. Male sex and hypercholesterolemia tended to
be higher in the DES compared with the BMS group. No
other differences in clinical or procedural characteristics were
observed. Table 2 shows the medication used during the
procedure, at discharge, and at follow-up: no differences
were found between the 2 groups up to 30-day follow-up.
Of note is that at 1 year, dual antiplatelet therapy wasfrequently used in DES compared with BMS group (93.4%
vs. 88.2%, p < 0.001).
Clinical outcomes. Clinical outcomes of the 2 trials at 1 year
are summarized in Online Table 1 no relevant heterogeneity
across the trials was observed in the analyses of all endpoints.
DES reduced DOCE by 42% compared with BMS
(hazard ratio [HR]: 0.58; 95% conﬁdence interval [CI]: 0.43
to 0.79; p < 0.001). Similarly, POCE was signiﬁcantly
reduced with DES (HR: 0.76; 95% CI: 0.61 to 0.96;
p ¼ 0.02) (Fig. 1). Figures 2 and 3 show the Kaplan-Meier
curves for DOCE, POCE, and their single components in
the 2 groups. Differences in favor of newer-generation DES
were driven by both a lower risk of repeat revasculariza-
tion of the target lesion (HR: 0.32; 95% CI: 0.20 to 0.52;
p < 0.001) and a lower risk of target-vessel infarction
(HR: 0.36; 95% CI: 0.14 to 0.91; p ¼ 0.032) (Fig. 4). No
differences were found between groups in terms of all-cause
mortality (HR: 0.90; 95% CI: 0.60 to 1.35; p ¼ 0.613) or
cardiac mortality (HR: 0.98; 95%CI: 0.63 to 1.51; p¼ 0.921).
The risk of either deﬁnite or deﬁnite/probable stent
thrombosis was lower among patients treated with DES
than BMS (HR: 0.35; 95% CI: 0.16 to 0.75; p < 0.01; HR:
0.53; 95% CI: 0.29 to 0.95; p ¼ 0.03, respectively) (Fig. 5).
Figure 2. One-Year Patient-Oriented Composite Outcome
Kaplan-Meier curves for the patient-oriented composite endpoint (A) and its individual component, all cause-death (B), any infarction (C), and any revascularization
(D) in each of the stent groups. Abbreviations as in Figure 1.
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59The beneﬁt was particularly evident within the ﬁrst 30 days
after implantation (Table 3).
The beneﬁt in terms of the primary endpoint of DES
over BMS was consistent across stratiﬁed analyses including
body mass index, left anterior descending artery, Throm-
bolysis In Myocardial Infarction ﬂow, thrombus aspiration,
multivessel treatment, lesion length, and vessel diameter.
An interaction with stent type was found for age (older than
65 vs. younger than 65 years of age), whereas a tendency
for association was observed for diabetes in the DOCE.
Interestingly, for deﬁnite/probable stent thrombosis, an
association with stent type was found with diabetes (Online
Figs. 1 to 3).
Discussion
This pooled analysis shows that new-generation DES, with
either durable or biodegradable polymer, improve safety and
efﬁcacy compared with BMS in appropriately powered
STEMI populations.Early generation DES have been associated with a
reduced risk of restenosis compared with BMS (16,17). For
this reason, they have quickly replaced BMS for many
clinical indications and are progressively used in more
complex coronary lesion subsets including off-label settings
(18,19). However, the early enthusiasm was dampened by
concerns related to the safety proﬁle of DES. In particular,
STEMI has been identiﬁed as an independent predictor
of stent thrombosis after DES implantation (20). It was
therefore postulated that although early generation DES
were associated with a lower risk of repeat revascularization,
this beneﬁt was offset by an increased risk of very late
(>1 year) stent thrombosis (18,19,21–23).
Biodegradable polymer DES and DES with more
biocompatible durable polymers have been developed with
the aim to reduce these adverse effects, related to the persis-
tence of a durable polymer or to a nonbiocompatible durable
polymer in the arterial wall (24–26). Recent experimental data
indicate a lower thrombogenicity of these DES compared
with BMS, suggesting a possible thromboresistant effect of
Figure 3. One-Year Device-Oriented Composite Endpoint
Kaplan-Meier curves for the device-oriented composite endpoint (A) and its individual component, cardiac death (B), target vessel infarction (C), and ischemia-driven
target lesion revascularization (D) in each of the stent groups. Abbreviations as in Figure 1.
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60polymer coatings during the early period (27). This may be
particularly important in patients with STEMI who carry
a higher baseline risk of early stent thrombosis because of
a large thrombus burden (28) and increased platelet activation
(29). In particular, the thromboresistance of biodegradable
polymer-based stents may be related to the presence ofFigure 4. Outcomes According to Target Vessel Reinfarction
Forrest plot with hazard ratios of revascularization and stent thrombosis according to
outcome is considered associated if it occurred in the 7 to þ 7 days from the targbiolimus A9, which is the limus analogue with the highest
lipophilicity used for DES (9). As the acute coronary lesions
predominantly consist of lipid-rich, ruptured plaques with
large necrotic cores (30), it may be hypothesized that the
increased lipophilicity of biolimus A9 may provide a more
rapid and homogeneous drug distribution, potentially leadingtheir association with target vessel reinfarction for the 2 stent groups. A single
et vessel reinfarction. Abbreviations as in Figure 1.
Figure 5. One-Year Stent Thrombosis
Kaplan-Meier curves for the deﬁnite (A) and deﬁnite/probable stent thrombosis (B) in each of the stent groups. Abbreviations as in Figure 1.
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61to a more potent anti-inﬂammatory and antithrombotic local
effects. This hypothesis requires, however, validation in
dedicated studies. In addition, the safety proﬁle of these
newer-generation DES appears to go beyond 1 year, with
a very low rate of stent thrombosis at long-term follow-up
(31–33).
The EXAMINATION and COMFORTABLE-AMI
trials recently individually tested the safety and efﬁcacy of
newer generation DES compared with BMS in STEMI at 1
year of follow-up. However, the power of the individual
trials to detect differences in rarely occurring adverse safety
endpoints, such as stent thrombosis, was inadequate and one
of the reasons to undertake the present analysis. The recently
published PROTECT trial is to date the ﬁrst study de-
signed to detect differences in stent thrombosis between
zotarolimus-eluting and sirolimus-eluting stents. However,the trial failed to show differences in terms of the safety
endpoint despite a large patient population, which may have
been related at least in part to the inclusion of lower-risk
patients. Thus, only 9% of patients presented with STEMI,
the clinical condition with the highest risk of stent throm-
bosis and ischemic endpoints (34).
Our meta-analysis shows in an appropriately powered
STEMI population that second-generation DES are safe
and efﬁcacious compared with BMS in terms of a reduced
rate of either device- and patient-oriented endpoints or stent
thrombosis during the ﬁrst year of follow-up. The ﬁndings
of the current analysis may be regarded as novel and
important for at least 2 reasons.
First, with respect to safety, our ﬁndings show for the ﬁrst
time a signiﬁcant and clinically important risk reduction for
deﬁnite stent thrombosis in favor of newer-generation DES
Table 3. Stent Thrombosis
Trial DES BMS HR* (95% CI) p Value HR* (95% CI) p Value
Stent thrombosis (deﬁnite early) COMFORTABLE-AMI 5 (0.9) 10 (1.8) 0.51 (0.17–1.48) 0.214 0.38 (0.17–0.85) 0.019
EXAMINATION 3 (0.4) 12 (1.6) 0.25 (0.07–0.88) 0.030
Stent thrombosis (deﬁnite acute) COMFORTABLE-AMI 1 (0.2) 3 (0.5) 0.34 (0.04–3.25) 0.347 0.33 (0.09–1.23) 0.099
EXAMINATION 2 (0.3) 6 (0.8) 0.33 (0.07–1.64) 0.176
Stent thrombosis (deﬁnite subacute) COMFORTABLE-AMI 5 (0.9) 10 (1.8) 0.51 (0.17–1.48) 0.214 0.40 (0.15–1.05) 0.063
EXAMINATION 1 (0.1) 6 (0.8) 0.17 (0.02–1.37) 0.095
Stent thrombosis (deﬁnite late) COMFORTABLE-AMIy 0 (0.0) 2 (0.4) 0.34 (0.04–3.23) 0.687 0.63 (0.14–2.75) 0.535
EXAMINATION 2 (0.3) 2 (0.3) 1.00 (0.14–7.07) 0.997
Values are n (%) of ﬁrst events. *Hazard ratios with continuity correction. yCOMFORTABLE-AMI p value from the Fisher exact test. Early ¼ 0 to 30 days (acute, 24 h; subacute, 1 to 30 days); late ¼ 31 to 365
days.
BMS ¼ bare-metal stent(s); CI ¼ conﬁdence interval; DES ¼ drug-eluting stent(s); HR ¼ hazard ratio.
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62compared with BMS during the ﬁrst year after stent
implantation in a thrombotic milieu such as STEMI. This
observation corroborates the above-mentioned experimental
and clinical data suggesting a thromboresistant role of the
respective polymer-drug combination (27,33).
Second, the target vessel myocardial infarction was less
frequent with newer-generation DES than BMS. This
difference in safety was not observed in previous randomized
trials comparing early generation DES with BMS among
patients with STEMI, (1–3,5) but is consistent with the
ﬁndings of a recent meta-analysis reporting a lower risk of
reinfarction during the ﬁrst year (35). It is interesting to note
that a reduction in acute/subacute stent thrombosis was able
to reduce target vessel reinfarction but not cardiac mortality.
Although the former is strictly dependent on the type of
stent implanted, the latter is multifactorial in a STEMI
population.
Taken together, these ﬁndings may be regarded as an
important step to change the treatment paradigm of STEMI
patients, suggesting not only a more effective but also safer
outcome after DES compared with BMS implantation.
It is unclear whether our results reﬂect a lack of beneﬁt in
diabetic patients. We are unaware of biological mechanisms
that might explain interactions with diabetes, and in view of
the lack of mechanisms and the large number of stratiﬁed
analyses, chance should also be considered as an explanation
of our ﬁndings.
Study limitations. First, this was not a randomized clinical
trial, but a pooled analysis of individual patient data from 2
different randomized clinical trials. However, the trials
primarily intended to investigate newer-generation DES
compared with BMS, consistent with the aim of the present
analysis. Moreover, our analysis showed no evidence of
heterogeneity across the trials, and pooled individual data
revealed no signiﬁcant and clinically important differences
between the 2 groups compared at baseline.
Longer follow-up is needed to conﬁrm that the safety
proﬁle, achieved during the ﬁrst year after implantation, is
sustained with persistence of the antirestenotic efﬁcacy andwithout an increase in very late stent thrombosis. However, in
previous studies and meta-analyses BES and EES have been
shown to reduce the risk of stent thrombosis beyond 1 year
compared, for example, with early generation sirolimus-eluting
stents, providing support for the improved long-term bio-
compatibility of newer-generation DES (31,32).
Conclusions
In patients with STEMI, newer-generation DES improved
safety and efﬁcacy compared with BMS throughout 1 year.
It remains to be determined whether these differences in
favor of newer-generation DES continue during long-term
follow-up.
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